EGFR and non-small cell lung carcinoma: In early-stage disease, adjuvant alectinib benefits resected ALK-positive NSCLC (April 2024), and adjuvant osimertinib improves overall survival (July 2023) in resected EGFR-mutant NSCLC [30,31].